End stage Knee Oa predictive tool 2 to 5 years now available online. using MOST and OAI open access data #EULAR2024 abst#0203 @RheumNow Can help in more efficient Knee OA clinical trials. https://t.co/AhhoczsuHU

#EULAR2024 Reminder … 🔺Anti-drug antibodies cause significant variability in Therapeutic drug levels 🔺10% have undetectable drug level after 3 months of Rx 🔺is therapeutic drug monitoring is beneficial? 🤔 https://t.co/ChgMnKPyFb

Cardiovascular risk prediction in #RA using #AI chest xray imaging improves accuracy abst#0146 @RheumNow #EULAR2024 https://t.co/wtF5Sel8Tx

steroid dose 120 mg , repeated if not in remission 12 wks on background MTX - no difference between groups @rheumnow #EULAR2024 https://t.co/gkqmElfOCp

Deep learning to predict if an #RA patient will benefit from treatment using MRIs abst#0182 Models are still not good for mainstream practice- but will be in the future! Lots of fine tuning required #EULAR2024 #EULARBest @rheumnow https://t.co/9yVN6CHLCv

dual IL 17 A & F nanobody typical response at 12 wks not significantly better - how many IL17 inhibs do we need? ⁦@RheumNow⁩ #EULAR2024 https://t.co/50dIKyO0e4

Was a full room #EULAR2024 for the SELECT-GCA presentation (upadacitinib in GCA positive study). Palpable excitement through the audience here in Vienna @RheumNow https://t.co/bFL6mqqFAa

Using data from a large population > 100 million people with SpA (predominantly PsA) from the TriNetX Global Collaborative Network, JAKi was not associated with increased risk of CVD, VTE or selected cancers, compared to TNFi or IL-17i #EULAR2024 Abstract P0231 @RheumNow https://t.co/Oi64BeWcmk

Patients with r-axSpA can be divided into subgroups with specific pain distribution profiles and sensory symptom profiles (Clusters 1,2,3) 1 with a diffuse distribution of pain over many pain regions indicates activation of the nociplastic pain mechanisms, 2 with pain localised… https://t.co/HsaBzlXzoc https://t.co/CpMPzNWptk

Molecular dissection of OA mechanisms brings some important pieces of knowledge and new potential therapeutic targets GWAS in hands OA #EULAR2024 @RheumNow https://t.co/L7iZgzmFtr

Get your sunscreen ready 🌞! Higher UV-B exposure asso w/ higher chance of reaching ACR/EULAR Boolean remission in RA pts treated w/ MTX monotherapy Now this could well be a surrogate for other socio demographic factors asso with better prognosis @RheumNow #EULAR2024 OP0153 https://t.co/k852O5psTM